2025
Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study
Bernstein J, Betschel S, Busse P, Banerji A, Wedner H, Manning M, Zaragoza-Urdaz R, Anderson J, Gagnon R, Baptist A, Soteres D, Lumry W, Craig T, Petroni D, Hsu F, Nova Estepan D, Juethner S, Watt M, Khutoryansky N, Zuraw B. Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World Study. Advances In Therapy 2025, 1-20. DOI: 10.1007/s12325-025-03226-3.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsLong-term prophylaxisHereditary angioedemaHAE attack ratesPost-baseline safety assessmentProphylaxis of hereditary angioedemaConclusionReal-world dataInjection site reactionsAttack rateReal-world studyYears of ageFemale patientsLanadelumabSite reactionsAdverse eventsFollow-upSafety signalsSafety dataEMPOWER studyPatientsDeficiency typeAngioedemaLow attack rateSustained effectPost-baselineAntidopaminergic Medications and Clinical Changes in Measures of Huntington's Disease: A Causal Analysis
Geva M, Goldberg Y, Schuring H, Tan A, Long J, Hayden M. Antidopaminergic Medications and Clinical Changes in Measures of Huntington's Disease: A Causal Analysis. Movement Disorders 2025, 40: 928-937. PMID: 40099482, PMCID: PMC12089908, DOI: 10.1002/mds.30164.Peer-Reviewed Original ResearchConceptsMeasures of clinical outcomeTotal motor scoreOutcome measuresUnified Huntington's Disease Rating ScaleHuntington's Disease Rating ScaleYears post-baselineEnroll-HD databaseFunctional outcome measuresManagement of Huntington's diseaseNew-user designAntidopaminergic medicationsHuntington's diseaseSymptom managementEnroll-HDClinical outcomesDisease Rating ScalePost-baselineMeasure of clinical progressionUnexposed cohortComposite Unified Huntington’s Disease Rating Scale,Motor scoresClinical measuresADM useAssociated with worse clinical outcomesRating ScaleAssociations between racial residential segregation and hypertensive disorders of pregnancy among Black women: The Coronary Artery Risk Development in Young Adults Study
Dodds L, Feaster D, Kershaw K, Gunderson E, Rundek T, Paidas M, Elfassy T. Associations between racial residential segregation and hypertensive disorders of pregnancy among Black women: The Coronary Artery Risk Development in Young Adults Study. International Journal Of Cardiology Cardiovascular Risk And Prevention 2025, 25: 200381. PMID: 40160698, PMCID: PMC11952018, DOI: 10.1016/j.ijcrp.2025.200381.Peer-Reviewed Original ResearchRacial residential segregationCoronary Artery Risk DevelopmentYoung Adults studyBlack womenRisk DevelopmentHypertensive disordersRacial health disparitiesCohort of BlackAssociated with HDPHypertensive disorders of pregnancyRisk of hypertensive disordersPhysical activityAdult studiesHealth disparitiesDisorders of pregnancyResidential segregationIncidence of HDPBaseline parityWhite adultsMaternal outcomesU.S. METHODSParous womenPost-baselineSelf-ReportGeneralized mixed models
2023
Brain-derived neurotrophic factor as a biomarker in cancer-related cognitive impairment among adolescent and young adult cancer patients
Ng D, Cheng I, Wang C, Tan C, Toh Y, Koh Y, Ke Y, Foo K, Chan R, Ho H, Chew L, bin Harunal Rashid M, Chan A. Brain-derived neurotrophic factor as a biomarker in cancer-related cognitive impairment among adolescent and young adult cancer patients. Scientific Reports 2023, 13: 16298. PMID: 37770565, PMCID: PMC10539508, DOI: 10.1038/s41598-023-43581-1.Peer-Reviewed Original ResearchConceptsCancer-related cognitive impairmentYoung adult cancer patientsBrain-derived neurotrophic factorAdult cancer patientsCambridge Neuropsychological Test Automated BatteryCancer participantsNon-cancer controlsPlasma brain-derived neurotrophic factorSociodemographic variablesBDNF levelsCognitive impairmentBrain-derived neurotrophic factor Val66MetCancer patientsAssociated with worse attentionNeurotrophic factorBrain-derived neurotrophic factor levelsAssociated with enhanced executive functionBaseline BDNF levelsFACT-CogPlasma BDNF levelsPsychological distressImprove cognitive functionBaseline cognitionPost-baselineEnzyme-linked immunosorbent assay
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply